Report cover image

Global Ceftriaxone Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 188 Pages
SKU # APRC20355388

Description

Summary

According to APO Research, The global Ceftriaxone market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Ceftriaxone is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Ceftriaxone is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Ceftriaxone is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Ceftriaxone is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Ceftriaxone include Qilu Pharmaceutical, Novartis, Baxter International, Orchid Pharma, Nectar Lifesciences, Lupin Pharmaceuticals, Hikma Pharmaceuticals, Aurobindo Pharma and ACS DOBFAR, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Ceftriaxone, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Ceftriaxone, also provides the sales of main regions and countries. Of the upcoming market potential for Ceftriaxone, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Ceftriaxone sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Ceftriaxone market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Ceftriaxone sales, projected growth trends, production technology, application and end-user industry.

Ceftriaxone Segment by Company

Qilu Pharmaceutical
Novartis
Baxter International
Orchid Pharma
Nectar Lifesciences
Lupin Pharmaceuticals
Hikma Pharmaceuticals
Aurobindo Pharma
ACS DOBFAR
Ceftriaxone Segment by Type

Intravenous Injection
Intramuscular Injection
Ceftriaxone Segment by Application

Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Ceftriaxone Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ceftriaxone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ceftriaxone and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ceftriaxone.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Ceftriaxone market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Ceftriaxone manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Ceftriaxone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Ceftriaxone in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

188 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Ceftriaxone Market Size, 2020 VS 2024 VS 2031
1.3 Global Ceftriaxone Market Size Estimates and Forecasts (2020-2031)
1.4 Global Ceftriaxone Sales Estimates and Forecasts (2020-2031)
1.5 Global Ceftriaxone Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Ceftriaxone Market Dynamics
2.1 Ceftriaxone Industry Trends
2.2 Ceftriaxone Industry Drivers
2.3 Ceftriaxone Industry Opportunities and Challenges
2.4 Ceftriaxone Industry Restraints
3 Ceftriaxone Market by Manufacturers
3.1 Global Ceftriaxone Revenue by Manufacturers (2020-2025)
3.2 Global Ceftriaxone Sales by Manufacturers (2020-2025)
3.3 Global Ceftriaxone Average Sales Price by Manufacturers (2020-2025)
3.4 Global Ceftriaxone Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Ceftriaxone Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Ceftriaxone Manufacturers, Product Type & Application
3.7 Global Ceftriaxone Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Ceftriaxone Market CR5 and HHI
3.8.2 Global Top 5 and 10 Ceftriaxone Players Market Share by Revenue in 2024
3.8.3 2024 Ceftriaxone Tier 1, Tier 2, and Tier 3
4 Ceftriaxone Market by Type
4.1 Ceftriaxone Type Introduction
4.1.1 Intravenous Injection
4.1.2 Intramuscular Injection
4.2 Global Ceftriaxone Sales by Type
4.2.1 Global Ceftriaxone Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Ceftriaxone Sales by Type (2020-2031)
4.2.3 Global Ceftriaxone Sales Market Share by Type (2020-2031)
4.3 Global Ceftriaxone Revenue by Type
4.3.1 Global Ceftriaxone Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Ceftriaxone Revenue by Type (2020-2031)
4.3.3 Global Ceftriaxone Revenue Market Share by Type (2020-2031)
5 Ceftriaxone Market by Application
5.1 Ceftriaxone Application Introduction
5.1.1 Retail Pharmacies
5.1.2 Online Pharmacies
5.1.3 Hospital Pharmacies
5.2 Global Ceftriaxone Sales by Application
5.2.1 Global Ceftriaxone Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Ceftriaxone Sales by Application (2020-2031)
5.2.3 Global Ceftriaxone Sales Market Share by Application (2020-2031)
5.3 Global Ceftriaxone Revenue by Application
5.3.1 Global Ceftriaxone Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Ceftriaxone Revenue by Application (2020-2031)
5.3.3 Global Ceftriaxone Revenue Market Share by Application (2020-2031)
6 Global Ceftriaxone Sales by Region
6.1 Global Ceftriaxone Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Ceftriaxone Sales by Region (2020-2031)
6.2.1 Global Ceftriaxone Sales by Region (2020-2025)
6.2.2 Global Ceftriaxone Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Ceftriaxone Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Ceftriaxone Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Ceftriaxone Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Ceftriaxone Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Ceftriaxone Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Ceftriaxone Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Ceftriaxone Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Ceftriaxone Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Ceftriaxone Revenue by Region
7.1 Global Ceftriaxone Revenue by Region
7.1.1 Global Ceftriaxone Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Ceftriaxone Revenue by Region (2020-2025)
7.1.3 Global Ceftriaxone Revenue by Region (2026-2031)
7.1.4 Global Ceftriaxone Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Ceftriaxone Revenue (2020-2031)
7.2.2 North America Ceftriaxone Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Ceftriaxone Revenue (2020-2031)
7.3.2 Europe Ceftriaxone Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Ceftriaxone Revenue (2020-2031)
7.4.2 Asia-Pacific Ceftriaxone Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Ceftriaxone Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Ceftriaxone Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Qilu Pharmaceutical
8.1.1 Qilu Pharmaceutical Comapny Information
8.1.2 Qilu Pharmaceutical Business Overview
8.1.3 Qilu Pharmaceutical Ceftriaxone Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Qilu Pharmaceutical Ceftriaxone Product Portfolio
8.1.5 Qilu Pharmaceutical Recent Developments
8.2 Novartis
8.2.1 Novartis Comapny Information
8.2.2 Novartis Business Overview
8.2.3 Novartis Ceftriaxone Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 Novartis Ceftriaxone Product Portfolio
8.2.5 Novartis Recent Developments
8.3 Baxter International
8.3.1 Baxter International Comapny Information
8.3.2 Baxter International Business Overview
8.3.3 Baxter International Ceftriaxone Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Baxter International Ceftriaxone Product Portfolio
8.3.5 Baxter International Recent Developments
8.4 Orchid Pharma
8.4.1 Orchid Pharma Comapny Information
8.4.2 Orchid Pharma Business Overview
8.4.3 Orchid Pharma Ceftriaxone Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Orchid Pharma Ceftriaxone Product Portfolio
8.4.5 Orchid Pharma Recent Developments
8.5 Nectar Lifesciences
8.5.1 Nectar Lifesciences Comapny Information
8.5.2 Nectar Lifesciences Business Overview
8.5.3 Nectar Lifesciences Ceftriaxone Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Nectar Lifesciences Ceftriaxone Product Portfolio
8.5.5 Nectar Lifesciences Recent Developments
8.6 Lupin Pharmaceuticals
8.6.1 Lupin Pharmaceuticals Comapny Information
8.6.2 Lupin Pharmaceuticals Business Overview
8.6.3 Lupin Pharmaceuticals Ceftriaxone Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Lupin Pharmaceuticals Ceftriaxone Product Portfolio
8.6.5 Lupin Pharmaceuticals Recent Developments
8.7 Hikma Pharmaceuticals
8.7.1 Hikma Pharmaceuticals Comapny Information
8.7.2 Hikma Pharmaceuticals Business Overview
8.7.3 Hikma Pharmaceuticals Ceftriaxone Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Hikma Pharmaceuticals Ceftriaxone Product Portfolio
8.7.5 Hikma Pharmaceuticals Recent Developments
8.8 Aurobindo Pharma
8.8.1 Aurobindo Pharma Comapny Information
8.8.2 Aurobindo Pharma Business Overview
8.8.3 Aurobindo Pharma Ceftriaxone Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Aurobindo Pharma Ceftriaxone Product Portfolio
8.8.5 Aurobindo Pharma Recent Developments
8.9 ACS DOBFAR
8.9.1 ACS DOBFAR Comapny Information
8.9.2 ACS DOBFAR Business Overview
8.9.3 ACS DOBFAR Ceftriaxone Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 ACS DOBFAR Ceftriaxone Product Portfolio
8.9.5 ACS DOBFAR Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Ceftriaxone Value Chain Analysis
9.1.1 Ceftriaxone Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Ceftriaxone Production Mode & Process
9.2 Ceftriaxone Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Ceftriaxone Distributors
9.2.3 Ceftriaxone Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.